Drugs@FDA document
GLYXAMBI Review · NDA 206073 SUPPL-21
Drugs@FDA document · BOEHRINGER INGELHEIM · Sep 24, 2021
Key facts
| Drug name | GLYXAMBI |
|---|---|
| Document type | Review |
| Application | NDA206073 |
| Submission | SUPPL-21 |
| Company | BOEHRINGER INGELHEIM |
| Document date | Sep 24, 2021 |
| FDA document | accessdata.fda.gov |
At a glance
- Efficacy-Labeling Change With Clinical Data Document categories
- 10–99 Documents for this application
- 1–9 USP chapters cited in this application's documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: